COMMUNIQUÉS West-GlobeNewswire

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

07/05/2024 - 14:30

- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 [...]

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

07/05/2024 - 14:30

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

07/05/2024 - 14:30

Biopharma industry veteran joins Scorpius’ leadership team DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development [...]

Palisade Bio Appoints Margery Fischbein to its Board of Directors

07/05/2024 - 14:30

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- [...]

IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

07/05/2024 - 14:30

FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK) (“BACK”) and [...]

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

07/05/2024 - 14:30

Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet [...]

Nanox to Participate in Three Upcoming Investor Conferences in May 2024

07/05/2024 - 14:30

PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will [...]

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

07/05/2024 - 14:30

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today [...]

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

07/05/2024 - 14:30

TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (OTC: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in [...]

BrightInsight Expands its Partnership with Google Cloud to Enhance the Patient Journey Through Generative AI

07/05/2024 - 14:05

BrightInsight is modernizing its development processes and patient companion apps with Google’s Gemini models, MedLM, and Vertex AI SAN JOSE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- BrightInsight, Inc, the trusted [...]

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

07/05/2024 - 14:01

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

07/05/2024 - 14:01

The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE [...]

Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

07/05/2024 - 14:00

AI-informed drug design enabled approval to dose within one year of project initiation Data highlight use of AI to engineer investigative allele selective antisense oligonucleotide treatment for baby with ultra-rare [...]

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

07/05/2024 - 14:00

Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR [...]

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

07/05/2024 - 14:00

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® [...]

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO

07/05/2024 - 14:00

LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the [...]

Amolyt Pharma dévoile les abstracts acceptés pour présentation aux congrès de la GRS, de l'ECE et de l'ENDO

07/05/2024 - 14:00

LYON, France et CAMBRIDGE, Mass., 07 mai 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, société spécialisée dans le développement de peptides thérapeutiques ciblant les maladies endocriniennes et métaboliques rares, a annoncé [...]

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

07/05/2024 - 14:00

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, [...]

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

07/05/2024 - 14:00

Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to [...]